Skip to content

Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients

Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06463236
Enrollment
1296
Registered
2024-06-17
Start date
2024-06-14
Completion date
2025-08-31
Last updated
2024-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia of Chronic Kidney Disease

Brief summary

This test aims to verify that the management process of renal anemia in maintenance hemodialysis patients can improve the hemoglobin compliance rate better than that of anemia management by primary doctors, and promote the system at the grassroots level to guide primary doctors in anemia management and improve the management standard of renal anemia in maintenance hemodialysis patients through prospective randomized controlled trials. To improve the anemia compliance rate of maintenance hemodialysis patients, and to improve the basic doctors' grasp of the anemia management guidelines, consensus and standard operating procedures.

Interventions

OTHERGuiding treatment

Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process

Experiential treatment by grassroots doctors

Sponsors

Hong Daqing
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

① Age over 18 years old; ② Receive regular hemodialysis at least twice a week for at least 3 months, and have no plans to stop hemodialysis within 6 months since the start of the trial; ③ The patient voluntarily participated in this study.

Exclusion criteria

* Patients who have planned to undergo kidney transplantation or terminate hemodialysis during the study period; ② Previous history of bone marrow hematopoietic system diseases, such as combined myelodysplastic syndrome, multiple myeloma, and other diseases; ③ Any known hereditary blood disease, such as thalassemia, sickle cell anemia, pure red blood cell aplasia, etc.; ④ Active or chronic gastrointestinal bleeding; ⑤ There was a severe infection within one week prior to screening.

Design outcomes

Primary

MeasureTime frameDescription
Changes in the one-year compliance rate of renal anemiaone yearChanges in renal anemia compliance rates between the experimental group and the control group within one year

Countries

China

Contacts

Primary ContactDaqing Hong
hongdaqing11@126.com17716168101

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026